The development of new treatments in MS has exploded. Currently there are at least 15 disease modifying agents available with more anticipated to be approved in the next few years….
Read More
Join RMMSC Medical Director Dr. Timothy Vollmer for an in-depth look at disease modifying therapies (DMTs) – the front line in our fight against MS. This webinar will give you…
According to the Social Security Administration, 25 percent of all people will need to receive disability benefits at some point in their lives. Thus everyone, but especially people with a…
Dr. Amanda Piquet’s presentation focuses on the rapidly evolving field of Autoimmune Neurology. She defines antibody-mediated diseases that are distinct from Multiple Sclerosis. Dr. Piquet also discuss newly recognized syndromes…
Michelle King, Director of the RMMSC’s King Adult Day Enrichment Program, presents a webinar exploring issues related to accessibility. Michelle will discuss: accessible transportation options, both local and when traveling (airlines,…
Summer heat can be a barrier to being active when you’re living with MS. In this webinar, several of our Certified Therapeutic Recreation Specialists as well as a Registered Nurse…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Enrique Alvarez answers some common questions on…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Timothy Vollmer answers some common questions on…
https://youtu.be/79-neCtENZ8 Join the RMMSC’s Dr. Enrique Alvarez as he discusses the latest developments in MS research, including those presented at the 2016 ECTRIMS conference in Europe. If you were not…
In this webinar, Dr. Teri Schreiner explores her specialty, the rare development of pediatric MS. While MS most often manifests in adults between 30 and 45, Dr. Schreiner treats cases in…
